Epic Sciences and Peter Kuhn’s CTC Technology Collaboration
Epic Sciences, Inc. has entered into an exclusive license and collaboration agreement with Peter Kuhn, Ph.D., and the USC Michelson Center for Convergent Bioscience. Dr. Kuhn is a founding member of the USC Michelson Center and leads USC’s Convergent Science Institute in Cancer (CSI-Cancer).
The collaboration will improve Epic’s platform and enable more precise characterization of rare circulating tumor cells (CTCs), which Epic is developing into liquid-biopsy diagnostics used to characterize a patient’s cancer, thereby helping the patient make better-informed treatment decisions.
“We are excited about this collaboration with Epic Sciences intended to accelerate our goals toward improved cancer patient outcomes,” said Dr. Kuhn, adding, “It also advances Epic Sciences further toward a data science company.”
Epic plans to offer this next-generation CTC technology as part of its suite of Comprehensive Cancer Profiling™ technologies.